

Long Complications of COVID Vaccination

Madison Yan, Sonja Schmidt*

Texas A&M University, 400 Bizzell St., College Station, TX 77840, USA

*: All correspondence should be sent to: Dr. Sonja Schmidt

Author's Contact: Ms. Madison Yan, M.Sc., Ph.D. Candidate, E-mail: madison.yan85@gmail.com; Dr. Sonja Schmidt, Ph.D.,

sonjaschmidt@gmail.com

DOI: <https://doi.org/10.15354/si.24.re1055>

Funding: No funding source declared.

COI: The authors declare no competing interest.

AI Declaration: The authors affirm that artificial intelligence did not contribute to the process of preparing the work.

COVID-19 vaccination has been a critical tool in the global fight against the pandemic, offering hope for a return to normalcy. While the immediate side effects of vaccination are well-documented and generally mild, concerns around potential long-term complications have emerged. This article explores the reported long-term complications following COVID vaccination, factors influencing these outcomes, and strategies for managing and addressing them. By delving into research findings and offering recommendations, we aim to provide valuable insights for individuals navigating the complexities of post-vaccination health concerns.

Keywords: COVID-19; Vaccination; Complications; Interventions; Post-vaccination Health

Science Insights, 2024 September 30; Vol. 45, No. 3, pp.1515-1522.

© 2024 Insights Publisher. All rights reserved.



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the [Creative Commons Attribution-NonCommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed by the Insights Publisher.

Introduction

IT HAS BEEN widely acknowledged that the COVID-19 immunization is an essential instrument in the battle against the worldwide pandemic (Sachdeva & Saha, 2021). Nevertheless, significant apprehensions have been expressed regarding possible enduring ramifications linked to the vaccination. Although most adults who have been vaccinated have experienced very minor adverse effects, there remains ambiguity over the potential for more severe, enduring consequences.

An inherent long-term drawback of the COVID vaccination is the pathogenesis of autoimmune diseases (Guo et al., 2023; Kamoi & Ohno-Matsui, 2024; Kim et al., 2024). Autoimmune diseases arise from the process of the body's immune system erroneously targeting and damaging healthy cells. Concerns have been expressed by certain specialists over the potential of the vaccine to elicit an immunological reaction in certain

individuals, resulting in a variety of symptoms including weariness, joint pain, and inflammation. Although the likelihood of acquiring an autoimmune disease following vaccination is minimal, it is worth noting that this possibility has not been completely dismissed.

A further possible long-term effect of the COVID vaccination is the occurrence of myocarditis or pericarditis, which refers to inflammation of the heart or its valves (De Sousa et al., 2024; Saputra et al., 2023; Tschöpe et al., 2020; Woo et al., 2021). Multiple instances of myocarditis and pericarditis have been documented after immunization, notably among adults in younger age groups. Although such instances are infrequent, they have sparked apprehensions regarding the possible enduring consequences of the vaccination on cardiovascular well-being.

In addition, there have been concerns expressed over the

possible enduring consequences of the mRNA technology employed in certain COVID vaccinations. MicroRNA (mRNA) vaccines function by introducing a minute segment of genetic material from the virus into the body, therefore stimulating an immune response (Acevedo-Whitehouse & Bruno, 2023; Stati et al., 2023). Concerns have been expressed by certain specialists over the potential long-term ramifications of this technique, such as the likelihood of gene mutations or other unforeseen outcomes.

Notwithstanding these worries, it is crucial to acknowledge that the advantages of the COVID vaccine much surpass the possible hazards. The vaccine has demonstrated an exceptional level of efficacy in averting severe disease, hospitalization, and mortality caused by COVID-19. Furthermore, it is an essential instrument in attaining herd immunity and effectively terminating the epidemic.

Overview of COVID-19 Vaccination

The formulation and dissemination of COVID-19 vaccines have played a pivotal role in the worldwide battle against the coronavirus epidemic. Since its onset in late 2019, scientists and pharmaceutical firms have been diligently striving to develop vaccinations that are both safe and efficacious in order to mitigate the transmission of the virus and ultimately preserve human lives (Dutta, 2020; Karpiński et al., 2020; Sumirtanuridin & Barliana, 2021).

Numerous COVID-19 vaccines have been produced and granted emergency use authorization by regulatory authorities worldwide (Kashte et al., 2021). These encompass mRNA vaccines, such as the vaccines developed by Pfizer-BioNTech and Moderna, viral vector vaccines, such as those developed by AstraZeneca and Johnson & Johnson, and protein subunit vaccines, such as the Novavax vaccine (Gote et al., 2023; Knežević et al., 2021). These vaccinations function by instructing the immune system on how to identify and combat the virus without inducing the illness.

To provide optimal protection against the virus, the COVID-19 immunization procedure usually entails the administration of two doses of the same vaccine, spaced several weeks apart (Grigoryan & Pulendran, 2020). Following vaccination, the immune system will accumulate antibodies that will provide protection against infection in the event of subsequent exposure to the virus (Goel et al., 2021). It is crucial to acknowledge that although immunization significantly decreases the likelihood of serious disease and mortality from COVID-19, there is still a possibility of acquiring the virus after receiving the vaccine. Hence, it is pivotal to persist in implementing preventive measures such as donning masks and regularly washing hands if needed.

Implementing widespread vaccination is essential for managing the transmission of COVID-19 and attaining herd immunity, which is the state in which enough individuals in a population have immunity to the virus, therefore effectively halting its spread (Fontanet & Cauchemez, 2020; Randolph & Barreiro, 2020). This measure would effectively safeguard susceptible population, including the elderly and individuals with pre-existing medical disorders, who face an elevated susceptibility to severe medical consequences resulting from COVID-19.

The implementation of this measure will also serve to mitigate the development of novel viral variants that may possess increased transmissibility or resistance to existing vaccinations (Cankat et al., 2023).

Ultimately, COVID-19 immunization is an essential way in combating the pandemic. The creation and dissemination of vaccinations that are both safe and effective have been an extraordinary achievement of contemporary scientific knowledge and will have a pivotal function in preserving lives and resolving the worldwide emergency. The vaccination of individuals when they meet the eligibility criteria is crucial in order to safeguard themselves, their family members, and their communities. Through collaborative efforts and adherence to public health protocols, we may collectively contribute to halting the transmission of the virus and restoring a state of normalcy.

Common Immediate Side Effects of COVID Vaccination

Soreness at the injection site is one of the most prevalent immediate adverse effects of COVID vaccination (Yan et al., 2021). This is typically moderate and will subside on its own within a few days. At the injection site, some individuals may also experience transient redness or swelling, which is not a cause for concern. These adverse effects are a typical reaction of the body to the vaccine and are indicative of the immune system's development of immunity against the virus.

Fatigue or lethargy is another prevalent adverse effect of COVID vaccination (Afrashtehfar et al., 2023; Dighriri et al., 2022). Upon obtaining the vaccine, numerous individuals report experiencing an increased level of fatigue, which is a typical reaction of the body as it establishes immunity. This fatigue usually subsides within a day or two and does not disrupt daily activities. It is crucial to rest and hydrate following the vaccination in order to mitigate this adverse effect.

Headaches are also a prevalent adverse effect of the COVID-19 vaccine (Nasergivehchi et al., 2023). Mild to moderate migraines may be experienced by certain individuals following vaccination; however, they typically subside within a day or two. If necessary, over-the-counter pain medications can be employed to ameliorate this symptom. It is necessary to acknowledge that migraines following vaccination are generally transient and should not be regarded as a cause for concern.

Another prevalent immediate adverse consequence of COVID vaccination is fever. A low-grade fever may develop in certain individuals following the vaccination, which is a typical immune system response to vaccine (Giannotta et al., 2023). Fever is indicative of the body's efforts to develop immunity to the infection. This adverse effect is typically mild and subsides on its own within a day or two. If you experience a fever after vaccination, it is crucial to maintain hydration and rest.

Joint pain and muscle discomfort are also frequent adverse effects of the COVID-19 vaccine. After receiving the vaccine, certain individuals may experience muscle or joint discomfort, aches, or stiffness (Afrashtehfar et al., 2023; Dighriri et al., 2022). This is typically moderate and will subside on its own within a few days. If necessary, over-the-counter pain medications can be employed to mitigate these symptoms. To alleviate muscle aches and joint discomfort, it is crucial to rest and refrain

from engaging in strenuous activities following vaccination.

Vomiting and nausea are potential adverse effects of the COVID-19 vaccine, although they are less prevalent. Mild nausea or vomiting may be experienced by certain individuals following vaccination; however, these symptoms are typically transient (Al-Rousan & Al-Najjar, 2024; Dighriri et al., 2022). If you are experiencing these symptoms following vaccination, it is crucial to maintain proper hydration and rest. It is advisable to consult with a physician if nausea or vomiting persist.

Another adverse effects of COVID vaccination include chills and shivering. After receiving the vaccine, certain individuals may experience shivering or shivers, which is a typical body response (Dighriri et al., 2022). These symptoms are generally mild and will subside on their own within a day or two. It is crucial to maintain a warm and hydrated environment following the vaccination to mitigate the symptoms of shivering and shivers.

Long-Term Complications Reported After COVID Vaccination

Although COVID vaccination has been demonstrated to be a successful method for reducing hospitalizations and fatalities and preventing the spread of the virus, there have been reports of long-term complications that have occurred as a result of vaccination.

Myocarditis, an inflammation of the heart muscle, is a frequent long-term complication that has been reported in the aftermath of COVID vaccination (Bozkurt et al., 2021; Saputra et al., 2023). This condition has been reported more frequently in younger males following the administration of mRNA-based vaccines, including Moderna and Pfizer-BioNTech (Almalki et al., 2023; Fadah et al., 2022; Rose et al., 2024). Chest pain, shortness of breath, and an irregular heartbeat are potential symptoms of myocarditis. However, some individuals may necessitate hospitalization and monitoring, despite the fact that the majority of myocarditis cases that occur following vaccination are mild and spontaneously resolve.

The immune system's attack on the nerves is a rare neurological disorder known as Guillain-Barre syndrome (GBS), which is another long-term complication that has been reported following COVID vaccination (Ilyas et al., 2022). Muscle weakness, numbness, and difficulty communicating or moving are among the symptoms of GBS. Although the likelihood of developing Guillain-Barre syndrome following vaccination is lower, it is crucial for individuals to be cognizant of the potential risks and to seek medical attention if they experience symptoms.

Other long-term complications reported after COVID vaccination include thrombocytopenia and blood clotting. These conditions have been associated with viral vector vaccines, including those manufactured by Johnson & Johnson and Astra-Zeneca (Faghihi et al., 2023; Knight et al., 2022; Oliver et al., 2020). Blood clots can be life-threatening if not treated promptly and can occur in a variety of body regions, such as the brain and lungs. Thrombocytopenia is a condition that is distinguished by a deficiency of platelets in the bloodstream, which can elevate the likelihood of bruising and hemorrhage (Saposnik et al., 2024).

Additionally, certain individuals have reported long-term

complications, including autoimmune disorders and hypersensitivity reactions, subsequent to their COVID-19 vaccination. Allergic reactions can manifest in a variety of ways, from mild symptoms like itching and urticaria to severe symptoms like anaphylaxis, a life-threatening reaction that necessitates immediate medical evaluation (Banerji et al., 2020; Edgerley et al., 2022; Escudero et al., 2022; Mahdiabadi & Rezaei, 2022; Wollina et al., 2021). Autoimmune disorders are the result of the immune system's mistaken attack on healthy cells and tissues in the body, which results in chronic inflammation and injury.

It is vital to acknowledge that the risks of rare side effects are outweighed by the overall benefit of vaccination in preventing severe illness and mortality from COVID-19, despite the fact that these long-term complications have been reported after COVID vaccination. The safety of COVID vaccines is still being monitored by the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), and vaccination is still recommended for eligible individuals (Safety of COVID-19 Vaccines, 2020).

Prior to receiving the COVID-19 vaccine, it is recommended that individuals consult with their healthcare provider regarding any preexisting medical conditions. This will reduce the likelihood of long-term complications. In addition, they should closely monitor for any symptoms of concern following vaccination and seek medical attention if necessary. Individuals can safeguard themselves from potential risks associated with COVID vaccination by remaining informed and taking a proactive approach to their health.

In short, although COVID vaccination has been crucial in regulating the virus's transmission and safeguarding public health, there have been reports of long-term complications that have arisen subsequent to vaccination. It is crucial for individuals to be cognizant of the potential advantages and disadvantages of vaccination and to make well-informed decisions regarding their health. Individuals can take proactive measures to protect their health and well-being in the context of the ongoing pandemic by collaborating closely with healthcare providers and monitoring for any symptoms of concern.

Factors Influencing Long-Term Complications

Age is one of the factors that affects the long-term complications of COVID-19 vaccination. It has been demonstrated that older individuals have a weakened immune response to vaccines, which may elevate the likelihood of long-term complications (Xu et al., 2023). Furthermore, older individuals are more likely to have underlying health conditions that could exacerbate any potential adverse effects of the vaccine (Park et al., 2024; Pereira et al., 2020).

Pre-existing health conditions are another factor that may affect long-term complications. Adverse reactions to the vaccine may be more prevalent in individuals with specific medical conditions, such as allergies or autoimmune disorders (Jara et al., 2022; Jaycox et al., 2023; Mahdiabadi & Rezaei, 2022; Rocco et al., 2021; Shan et al., 2024). It is crucial for individuals with underlying health conditions to consult with their healthcare provider prior to receiving a vaccination in order to address the potential risks and benefits.

The likelihood of long-term complications can also be in-

fluenced by the type of COVID-19 vaccine that is administered. The constituents and mechanisms of action of various vaccines may differ, potentially leading to a variety of adverse reactions and side effects (Bhandari et al., 2022; Fragkou & Dimopoulou, 2021; Kouhpayeh & Ansari, 2022; Mushtaq et al., 2022). Long-term complications, such as inflammation or allergic reactions, may result from some people being more sensitive to specific vaccine components.

Long-term complications of COVID-19 vaccination may be influenced by genetic factors as well. The risk of adverse reactions may be elevated by specific genetic variations that can influence the immune system's response to the vaccine (Bolze et al., 2022). The identification of individuals who are at a higher risk of long-term complications following vaccination may be facilitated by genetic testing and personalized medicine approaches.

The probability of long-term complications can also be influenced by the schedule and spacing of vaccine doses. Upon receiving a booster dose of the COVID vaccine, certain individuals may experience more severe adverse effects due to the increased immune response (Park et al., 2024). It is crucial for individuals to adhere to the recommended vaccine schedule and to address any apprehensions with their healthcare provider.

The occurrence of long-term complications following COVID-19 vaccination can also be influenced by environmental factors, such as exposure to other viruses or bacteria. Individuals who are currently battling an infection or have a compromised immune system may be more susceptible to adverse reactions from the vaccine (Fazal et al., 2022; Yoshida et al., 2023). It is crucial for individuals to prioritize their overall health and well-being in order to mitigate the risk of complications.

The probability of long-term complications from COVID-19 vaccination can also be influenced by psychological factors, such as anxiety or tension. If an individual is experiencing anxiety or overwhelm, they may be more susceptible to adverse reactions or side effects (Afrashtehfar et al., 2023; Taylor & Asmundson, 2021). The risk of complications can be mitigated by practicing relaxation techniques, obtaining support from loved ones, and maintaining a positive mindset.

The occurrence of long-term complications following vaccination can also be influenced by social factors, such as access to healthcare and vaccination information. Adverse reactions may be more prevalent among individuals who have inadequate healthcare services or inadequate information regarding the vaccine (Afrashtehfar et al., 2023). Equitable access to vaccines and the provision of transparent and comprehensible information to the public are crucial for public health authorities.

Lastly, the immune response to COVID-19 vaccination and the likelihood of long-term complications can be influenced by lifestyle factors, including diet and exercise. Individuals who adhere to a healthy lifestyle, which encompasses regular physical activity and a balanced diet, may have a more robust immune system that is better equipped to withstand the vaccine (Goel et al., 2021; Lam et al., 2024). It is crucial for individuals to prioritize their health and well-being both before and after receiving vaccinations in order to mitigate the risk of complications.

Managing and Addressing Long-Term Complications

A limited number of individuals who have received the COVID-19 vaccine have experienced myocarditis. This condition has been observed most frequently in younger males, particularly following the administration of mRNA vaccines (Elhassan et al., 2021; Rose et al., 2024; Srivastava et al., 2024). Myocarditis management entails the provision of supportive care to mitigate inflammation and prevent complications, as well as the monitoring of symptoms such as palpitations, shortness of breath, and chest pain. Hospitalization and medication administration, including corticosteroids or anti-inflammatory pharmaceuticals, may be necessary for patients with myocarditis.

GBS is a rare neurological disorder that results in muscle weakness and paralysis. It is another potential long-term complication that has been reported in tandem with COVID-19 vaccination (Ilyas et al., 2022). A limited number of individuals who have received the Johnson & Johnson vaccine have been observed to have GBS (Hilts et al., 2022; Korem et al., 2020). Prompt diagnosis and treatment are essential for the management of GBS, as they mitigate the risk of long-term disability. Supportive care, hospitalization, and treatment with immunoglobulins or plasma exchange may be necessary for patients with GBS to expedite recovery and mitigate the risk of complications.

Other potential long-term complications, such as thrombosis with thrombocytopenia syndrome (TTS), have been reported following COVID-19 vaccination. TTS is an uncommon blood clotting disorder that has been associated with some of the adenovirus-based vaccines (Haimei, 2021; Mercadé-Besora et al., 2024; Shan et al., 2024). Prompt diagnosis and treatment are essential for the management of TTS, as they prevent severe complications such as organ injury or stroke. Blood thinners, hospitalization, and frequent monitoring may be necessary for patients with TTS to guarantee a safe recovery.

Healthcare providers must be cognizant of the potential long-term complications that may result from COVID-19 vaccination and must monitor patients for any signs or symptoms of these complications. It is essential to promptly diagnose and administer treatment to patients who experience adverse reactions to vaccines in order to mitigate the risk of severe complications and guarantee a favorable outcome. Furthermore, public health officials should maintain a vigilant approach to the safety of the vaccines and offer revised recommendations for the management of long-term complications as new information becomes available.

Conclusion

Individuals who are contemplating the receipt of the COVID-19 vaccine are concerned about the potential long-term complications. Although short-term side effects, including mild fever, fatigue, and injection site discomfort, are prevalent and typically subside within a few days, there is ongoing research on the potential long-term adverse effects. Nevertheless, clinical trials and real-world studies have demonstrated that COVID vaccinations are associated with exceedingly rare severe long-term complications. The risks of any potential adverse reactions are significantly outweighed by the advantages of vaccination in prevent-

ing severe illness, hospitalization, and mortality. In order to guarantee the safety and efficacy of COVID vaccines in the long

term, healthcare professionals must monitor and report any unusual or severe reactions that occur following vaccination. ■

References

- Acevedo-Whitehouse, K., & Bruno, R. (2023). Potential health risks of mRNA-based vaccine therapy: A hypothesis. *Medical Hypotheses*, 171, 111015. DOI: <https://doi.org/10.1016/j.mehy.2023.111015>
- Afrashtehfar, K. I., Jurado, C. A., Abu-Fanas, S. H., & Jaber, M. A. (2023). Health and well-being through COVID-19 vaccination: Physical, oral, and psychological effects. *International Journal of Environmental Research and Public Health*, 20(4), 3117. DOI: <https://doi.org/10.3390/ijerph20043117>
- Almalki, M. E., Alshumrani, F. A., Almalki, H. A., Saati, A. A., Alzahrani, S. E., & Khouj, S. M. (2023). Regional myopericarditis mimicking inferior myocardial infarction following COVID-19 vaccination: A rare adverse event. *Cureus* 15(6), e41168. DOI: <https://doi.org/10.7759/cureus.41168>
- Al-Rousan, N., & Al-Najjar, H. (2024). Evaluation of the effects of MERCK, MODERNA, PFIZER/BioNTech, and JANSSEN COVID-19 vaccines on vaccinated people: A metadata analysis. *Informatics in Medicine Unlocked*, 49, 101564. DOI: <https://doi.org/10.1016/j.imu.2024.101564>
- Banerji, A., Wickner, P. G., Saff, R., Stone, C. A., Robinson, L. B., Long, A. A., Wolfson, A. R., Williams, P., Khan, D. A., Phillips, E., & Blumenthal, K. G. (2020). mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. *The Journal of Allergy and Clinical Immunology in Practice*, 9(4), 1423-1437. DOI: <https://doi.org/10.1016/j.jaip.2020.12.047>
- Bhandari, B., Rayamajhi, G., Lamichhane, P., & Shenoy, A. K. (2022). Adverse events following immunization with COVID-19 vaccines: A narrative review. *Bio-Med Research International*, 2022, 1-11. DOI: <https://doi.org/10.1155/2022/2911333>
- Bolze, A., Mogensen, T. H., Zhang, S., Abel, L., Andreakos, E., Arkin, L. M., Borghesi, A., Brodin, P., Hagin, D., Novelli, G., Okada, S., Peter, J., Renia, L., Severe, K., Tiberghien, P., Vinh, D. C., Aiuti, A., Al-Muhsen, S., Al-Mulla, F., . . . Hsieh, E. W. Y. (2022). Decoding the human genetic and immunological basis of COVID-19 mRNA vaccine-induced myocarditis. *Journal of Clinical Immunology*, 42(7), 1354-1359. DOI: <https://doi.org/10.1007/s10875-022-01372-9>
- Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis with COVID-19 mRNA vaccines. *Circulation*, 144(6), 471-484. DOI: <https://doi.org/10.1161/circulationaha.121.056135>
- Cankat, S., Demael, M. U., & Swadling, L. (2023). In search of a pan-coronavirus vaccine: Next-generation vaccine design and immune mechanisms. *Cellular and Molecular Immunology*, 21(2), 103-118. DOI: <https://doi.org/10.1038/s41423-023-01116-8>
- De Sousa, P. M. B., Silva, E. A., Campos, M. a. G., Lages, J. S., Da Graça Carvalho Frazão Corrêa, R., & Silva, G. E. B. (2024). Fatal myocarditis following COVID-19 mRNA immunization: A case report and differential diagnosis review. *Vaccines*, 12(2), 194. DOI: <https://doi.org/10.3390/vaccines12020194>
- Dighriri, I. M., Alhusayni, K. M., Mobarki, A. Y., Aljerary, I. S., Alqurashi, K. A., Aljuaid, F. A., Alamri, K. A., Mutwalli, A. A., Maashi, N. A., Aljohani, A. M., Alqarni, A. M., Alfaqih, A. E., Moazam, S. M., Almutairi, M. N., & Almutairi, A. N. (2022). Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) side effects: A systematic review. *Cureus*, 14(3), e23526. DOI: <https://doi.org/10.7759/cureus.23526>
- Dutta, A. K. (2020). Vaccine against Covid-19 disease - Present status of development. *The Indian Journal of Pediatrics*, 87(10), 810-816. DOI: <https://doi.org/10.1007/s12098-020-03475-w>
- Edgerley, S., Jeimy, S., & Zhu, R. (2022). Adverse cutaneous reactions after mRNA SARS-CoV-2 vaccination in 3 patients: A spectrum of severity. *Canadian Medical Association Journal*, 194(23), E807-E811. DOI: <https://doi.org/10.1503/cmaj.220435>
- Elhassan, M., Ahmad, H., Mohamed, M., Saidahmed, O., & Elhassan, A. E. (2021). From muscles to wires: Report of two cases and literature review on COVID-19 vaccination and cardiac conduction disturbance. *Cureus*, 13(10), e18805. DOI: <https://doi.org/10.7759/cureus.18805>
- Escudero, C., Prieto-Montañó, P., & Audicana, M. T. (2022). Adverse reactions to anti-infective vaccines: An emerging problem in the COVID-19 era. *Current Treatment Options in Allergy*, 9(3), 250-272. DOI: <https://doi.org/10.1007/s40521-022-00311-8>
- Fadah, K., Abolbashari, M., Ojha, C., & Alkhateeb, H. (2022). Acute myopericarditis after first dose of mRNA-1273 SARS-CoV-2 vaccine in a young adult. *Cureus*, 14(2), e22111. DOI: <https://doi.org/10.7759/cureus.22111>
- Faghihi, H., Mottaghi-Dastjerdi, N., Sharifzadeh, M., & Kakavandi, N. R. (2023). ChAdOx1 nCoV-19 vaccine and thrombosis with thrombocytopenia syndrome among adults: A systematic review. *Advanced Pharmaceutical Bulletin*, 13(4), 723-735. DOI: <https://doi.org/10.34172/apb.2023.081>
- Fazal, Z. Z., Sen, P., Joshi, M., Ravichandran, N., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Day, J., Makol, A., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., Nikiphorou, E., Tan, A. L., Chatterjee, T., . . . Arredondo, G. (2022). COVAD survey 2 long-term outcomes: Unmet need and protocol. *Rheumatology International*, 42(12), 2151-2158. DOI: <https://doi.org/10.1007/s00296-022-05157-6>
- Fontanet, A., & Cauchemez, S. (2020). COVID-19 herd immunity: Where are we? *Nature Reviews. Immunology*, 20(10), 583-584. DOI:

- <https://doi.org/10.1038/s41577-020-00451-5>
- Fragkou, P. C., & Dimopoulou, D. (2021). Serious complications of COVID-19 vaccines: A mini-review. *Metabolism Open*, 12, 100145. DOI: <https://doi.org/10.1016/j.metop.2021.100145>
- Giannotta, G., Murrone, A., & Giannotta, N. (2023). COVID-19 mRNA vaccines: The molecular basis of some adverse events. *Vaccines*, 11(4), 747. DOI: <https://doi.org/10.3390/vaccines11040747>
- Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., Gouma, S., Kuri-Cervantes, L., Hicks, P., Dysinger, S., Hicks, A., Sharma, H., Herring, S., Korte, S., Baxter, A. E., . . . Wherry, E. J. (2021). mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. *Science*, 374(6572), abm0829. DOI: <https://doi.org/10.1126/science.abm0829>
- Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023). A comprehensive review of mRNA vaccines. *International Journal of Molecular Sciences*, 24(3), 2700. DOI: <https://doi.org/10.3390/ijms24032700>
- Grigoryan, L., & Pulendran, B. (2020). The immunology of SARS-CoV-2 infections and vaccines. *Seminars in Immunology*, 50, 101422. DOI: <https://doi.org/10.1016/j.smim.2020.101422>
- Guo, M., Liu, X., Chen, X., & Li, Q. (2023). Insights into new-onset autoimmune diseases after COVID-19 vaccination. *Autoimmunity Reviews*, 22(7), 103340. DOI: <https://doi.org/10.1016/j.autrev.2023.103340>
- Haimeiri, M. (2021). Concern about the adverse effects of thrombocytopenia and thrombosis after adenovirus-vectored COVID-19 vaccination. *Clinical and Applied Thrombosis/Hemostasis*, 27, 107602962110401. DOI: <https://doi.org/10.1177/10760296211040110>
- Hilts, A., Schreiber, A., & Singh, A. (2022). A clinical case of COVID-19 vaccine-associated Guillain-Barré syndrome. *American Journal of Case Reports*, 23, e936896. DOI: <https://doi.org/10.12659/ajcr.936896>
- Ilyas, U., Umar, Z., Bhangal, R., Shah, D., & Fayman, B. (2022). Guillain-Barré syndrome: A sequela of the original COVID-19 infection or vaccination. *Cureus*, 14(8), e28044. DOI: <https://doi.org/10.7759/cureus.28044>
- Jara, L. J., Vera-Lastra, O., Mahroum, N., Pineda, C., & Shoenfeld, Y. (2022). Autoimmune post-COVID vaccine syndromes: Does the spectrum of autoimmune/inflammatory syndrome expand? *Clinical Rheumatology*, 41(5), 1603-1609. DOI: <https://doi.org/10.1007/s10067-022-06149-4>
- Jaycox, J. R., Lucas, C., Yildirim, I., Dai, Y., Wang, E. Y., Monteiro, V., Lord, S., Carlin, J., Kita, M., Buckner, J. H., Ma, S., Campbell, M., Ko, A., Omer, S., Lucas, C. L., Speake, C., Iwasaki, A., & Ring, A. M. (2023). SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. *Nature Communications*, 14(1), 1299. DOI: <https://doi.org/10.1038/s41467-023-36686-8>
- Kamoi, K., & Ohno-Matsui, K. (2024). Long vax in the eye: Long post-COVID vaccination syndrome presenting with frosted branch angiitis. *Diseases*, 12(2), 36. DOI: <https://doi.org/10.3390/diseases12020036>
- Karpiński, T. M., Ożarowski, M., Seremak-Mrozikiewicz, A., Wolski, H., & Włodkowiec, D. (2020). The 2020 race towards SARS-CoV-2 specific vaccines. *Theranostics*, 11(4), 1690-1702. DOI: <https://doi.org/10.7150/thno.53691>
- Kashte, S., Gulbake, A., El-Amin, S. F., III, & Gupta, A. (2021). COVID-19 vaccines: Rapid development, implications, challenges and future prospects. *Human Cell*, 34(3), 711-733. DOI: <https://doi.org/10.1007/s13577-021-00512-4>
- Kim, M. S., Lee, H., Lee, S. W., Kwon, R., Rhee, S. Y., Lee, J. A., Koyanagi, A., Smith, L., Fond, G., Boyer, L., Lee, J., Rahmati, M., Shin, J., Min, C., Shin, J. I., & Yon, D. K. (2024). Long-term autoimmune inflammatory rheumatic outcomes of COVID-19. *Annals of Internal Medicine*, 177(3), 291-302. DOI: <https://doi.org/10.7326/m23-1831>
- Knezevic, I., Liu, M. A., Peden, K., Zhou, T., & Kang, H. (2021). Development of mRNA vaccines: Scientific and regulatory issues. *Vaccines*, 9(2), 81. DOI: <https://doi.org/10.3390/vaccines9020081>
- Knight, R., Walker, V., Ip, S., Cooper, J. A., Bolton, T., Keene, S., Denholm, R., Akbari, A., Abbasizanjani, H., Torabi, F., Omigie, E., Hollings, S., North, T., Toms, R., Jiang, X., Di Angelantonio, E., Denaxas, S., Thygesen, J. H., Tomlinson, C., . . . Sterne, J. A. (2022). Association of COVID-19 with major arterial and venous thrombotic diseases: A population-wide cohort study of 48 million adults in England and Wales. *Circulation*, 146(12), 892-906. DOI: <https://doi.org/10.1161/circulationaha.122.060785>
- Korem, S., Gandhi, H., & Dayag, D. B. (2020). Guillain-Barré syndrome associated with COVID-19 disease. *BMJ Case Reports*, 13(9), e237215. DOI: <https://doi.org/10.1136/bcr-2020-237215>
- Kouhpayeh, H., & Ansari, H. (2022). Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. *International Immunopharmacology*, 109, 108906. DOI: <https://doi.org/10.1016/j.intimp.2022.108906>
- Lam, I. C. H., Zhang, R., Man, K. K. C., Wong, C. K. H., Chui, C. S. L., Lai, F. T. T., Li, X., Chan, E. W. Y., Lau, C. S., Wong, I. C. K., & Wan, E. Y. F. (2024). Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. *Nature Communications*, 15(1), 1716. DOI: <https://doi.org/10.1038/s41467-024-45953-1>
- Mahdiabadi, S., & Rezaei, N. (2022). Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity. *Health Science Reports*, 5(5), e787. DOI: <https://doi.org/10.1002/hsr2.787>
- Mercadé-Besora, N., Li, X., Kolde, R., Trinh, N. T., Sanchez-Santos, M. T., Man, W. Y., Roel, E., Reyes, C., Delmestri, A., Nordeng, H. M. E., Uusküla, A., Duarte-Salles, T., Prats, C., Prieto-Alhambra, D., Jödicke, A. M., & Català, M. (2024). The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications. *Heart*, 110(9), 635-643. DOI: <https://doi.org/10.1136/heartjnl-2023-323483>
- Mushtaq, H. A., Khedr, A., Koritala, T., Bartlett, B. N., Jain, N. K., & Khan, S. A. (2022). A review of adverse effects of COVID-19 vaccines. *Infezioni in Medicina*, 30(1), 1-10. DOI: <https://doi.org/10.53854/liim-3001-1>
- Nasergivehchi, S., Togha, M., Jafari, E., Sheikhvatan, M., & Shahamati, D. (2023). Headache following vaccination against COVID-19 among healthcare

- workers with a history of COVID-19 infection: A cross-sectional study in Iran with a meta-analytic review of the literature. *Head & Face Medicine*, 19(1), 19. DOI: <https://doi.org/10.1186/s13005-023-00363-4>
- Oliver, S. E., Gargano, J. W., Marin, M., Wallace, M., Curran, K. G., Chamberland, M., McClung, N., Campos-Outcalt, D., Morgan, R. L., Mbaeyi, S., Romero, J. R., Talbot, H. K., Lee, G. M., Bell, B. P., & Dooling, K. (2020). The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine — United States, December 2020. *MMWR Morbidity and Mortality Weekly Report*, 69(50), 1922-1924. DOI: <https://doi.org/10.15585/mmwr.mm6950e2>
- Park, H. J., Gonsalves, G. S., Tan, S. T., Kelly, J. D., Rutherford, G. W., Wachter, R. M., Schechter, R., Paltiel, A. D., & Lo, N. C. (2024). Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. *Nature Communications*, 15(1), 1883. DOI: <https://doi.org/10.1038/s41467-024-45549-9>
- Pereira, B., Xu, X., & Akbar, A. N. (2020). Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. *Frontiers in Immunology*, 11, 583019. DOI: <https://doi.org/10.3389/fimmu.2020.583019>
- Randolph, H. E., & Barreiro, L. B. (2020). Herd immunity: Understanding COVID-19. *Immunity*, 52(5), 737-741. DOI: <https://doi.org/10.1016/j.immuni.2020.04.012>
- Rocco, J. M., Mallarino-Haeger, C., Randolph, A. H., Ray, S. M., Schechter, M. C., Zerbe, C. S., Holland, S. M., & Sereti, I. (2021). Hyperinflammatory syndromes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccination in individuals with underlying immune dysregulation. *Clinical Infectious Diseases*, 75(1), e912-e915. DOI: <https://doi.org/10.1093/cid/ciab1024>
- Rose, J., Hulscher, N., & McCullough, P. A. (2024). Determinants of COVID-19 vaccine-induced myocarditis. *Therapeutic Advances in Drug Safety*, 15, 20420986241226566. DOI: <https://doi.org/10.1177/20420986241226566>
- Sachdeva, A., & Saha, A. (2021). COVID-19 vaccine: A way out of crisis. In *IntechOpen eBooks*. DOI: <https://doi.org/10.5772/intechopen.98736>
- Safety of COVID-19 Vaccines. (2020, February 10). CDC. Last access: August 10, 2024, Available at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html?s_cid=10508:covid%20vaccine%20long%20term%20side%20effects:s_em.ga:p:RG:GM:gen:PTN:FY21
- Saposnik, G., Bushnell, C., Coutinho, J. M., Field, T. S., Furie, K. L., Galadanci, N., Kam, W., Kirkham, F. C., McNair, N. D., Singhal, A. B., Thijs, V., & Yang, V. X. (2024). Diagnosis and management of cerebral venous thrombosis: A scientific statement from the American Heart Association. *Stroke*, 55(3), e77-e90. DOI: <https://doi.org/10.1161/str.0000000000000456>
- Saputra, P. B. T., Kurniawan, R. B., Trilistyati, D., Farabi, M. J. A., Susilo, H., Alsagaff, M. Y., Oktaviono, Y. H., Sutanto, H., Gusnanto, A., & Wungu, C. D. K. (2023). Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases. *Biomolecules and Biomedicine*, 23(4), 546-567. DOI: <https://doi.org/10.17305/bb.2022.8779>
- Shan, J., Hu, X., Chen, T., Wang, Y., Huang, B., Xin, Y., & Xu, H. (2024). COVID-19 vaccination and the risk of autoimmune diseases: A Mendelian randomization study. *Frontiers in Public Health*, 12, 1322140. DOI: <https://doi.org/10.3389/fpubh.2024.1322140>
- Srivastava, A., Sundararaj, S. N., Bhatia, J., & Arya, D. S. (2024). Understanding long COVID myocarditis: A comprehensive review. *Cytokine*, 178, 156584. DOI: <https://doi.org/10.1016/j.cyto.2024.156584>
- Stati, G., Amerio, P., Nubile, M., Sancilio, S., Rossi, F., & Di Pietro, R. (2023). Concern about the effectiveness of mRNA vaccination technology and its long-term safety: Potential interference on miRNA machinery. *International Journal of Molecular Sciences*, 24(2), 1404. DOI: <https://doi.org/10.3390/ijms24021404>
- Sumirtanurdin, R., & Barliana, M. I. (2021). Coronavirus disease 2019 vaccine development: An overview. *Viral Immunology*, 34(3), 134-144. DOI: <https://doi.org/10.1089/vim.2020.0119>
- Taylor, S., & Asmundson, G. J. (2021). Immunization stress-related responses: Implications for vaccination hesitancy and vaccination processes during the COVID-19 pandemic. *Journal of Anxiety Disorders*, 84, 102489. DOI: <https://doi.org/10.1016/j.janxdis.2021.102489>
- Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, A. L. P., Cooper, L. T., Felix, S. B., Hare, J. M., Heidecker, B., Heymans, S., Hübner, N., Kelle, S., Klingel, K., Maatz, H., Parwani, A. S., Spillmann, F., Starling, R. C., Tsutsui, H., Seferovic, P., & Van Linthout, S. (2020). Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. *Nature Reviews Cardiology*, 18(3), 169-193. DOI: <https://doi.org/10.1038/s41569-020-00435-x>
- Wollina, U., Chiriac, A., Kocic, H., Koch, A., & Brzezinski, P. (2021). Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—A narrative review. *Wiener Medizinische Wochenschrift*, 172(3-4), 63-69. DOI: <https://doi.org/10.1007/s10354-021-00876-0>
- Woo, W., Kim, A., Yon, D. K., Lee, S. W., Hwang, J., Jacob, L., Koyanagi, A., Kim, M., Moon, D. H., Jung, J., Choi, J., Jung, S. Y., Eun, L., Lee, S., Shin, J., & Smith, L. (2021). Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. *Journal of Medical Virology*, 94(4), 1566-1580. DOI: <https://doi.org/10.1002/jmv.27501>
- Xu, K., Wang, Z., Qin, M., Gao, Y., Luo, N., Xie, W., Zou, Y., Wang, J., & Ma, X. (2023). A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. *Frontiers in Immunology*, 14, 1113156. DOI: <https://doi.org/10.3389/fimmu.2023.1113156>
- Yan, Z., Yang, M., & Lai, C. (2021). COVID-19 Vaccinations: A comprehensive review of their safety and efficacy in special populations. *Vaccines*, 9(10), 1097. DOI: <https://doi.org/10.3390/vaccines9101097>
- Yoshida, M., Kobashi, Y., Kawamura, T., Shimazu, Y., Nishikawa, Y., Omata, F., Saito, H., Yamamoto, C., Zhao, T., Takita, M., Ito, N., Tatsuno, K., Kaneko, Y., Nakayama, A., Kodama, T., Wakui, M., Takahashi, K., & Tsubokura, M. (2023). Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus

Received: July 05, 2024 | Revised: August 16, 2024 | Accepted: August 19, 2024
